HTEC or IHI or RSPH

Key Takeaways

• HTEC offers a thematic focus on global healthcare technology innovation with 61 holdings and higher expense ratio of 0.68%, emphasizing growth-oriented firms in health tech (86% allocation).
• IHI provides concentrated U.S. medical devices exposure via market-cap weighting, with 49 holdings, top-heavy structure (top 10 at ~75%), and lowest expense ratio at 0.38%.
• RSPH delivers diversified equal-weight access to S&P 500 healthcare stocks (60 holdings), balancing health technology (66%) and services (22%), with a 0.40% expense ratio and quarterly rebalancing.
• IHI and RSPH exhibit higher liquidity and AUM compared to smaller HTEC, suiting different risk profiles: thematic growth (HTEC), specialized devices (IHI), broad sector blend (RSPH).
• Structural differences highlight HTEC's innovation tilt versus IHI's device focus and RSPH's reduced concentration risk through equal weighting.
• Cost efficiency favors IHI, while diversification depth supports RSPH for broad healthcare positioning.

Introduction

HTEC, IHI, and RSPH represent varied strategic approaches within the healthcare sector, a resilient segment amid economic uncertainty and aging demographics. HTEC targets global healthcare technology innovators, IHI focuses on U.S. medical device manufacturers, and RSPH applies equal-weighting to S&P 500 healthcare constituents for balanced exposure. These ETFs compete in overlapping themes but differ in scope—narrow thematic (HTEC), specialized subsector (IHI), and broad sector (RSPH)—offering investors tiered options from high-growth innovation to stable diversification. Comparing them reveals trade-offs in concentration, costs, and sensitivity to tech-driven healthcare trends like AI diagnostics and robotics.

ROBO Global Healthcare Technology and Innovation ETF (HTEC) Overview

The ROBO Global Healthcare Technology and Innovation ETF (HTEC) is a thematic passive ETF tracking the ROBO Global Healthcare Technology and Innovation Index. Launched in 2019, it holds 61 stocks selected for involvement in healthcare tech sub-themes like genomics, telehealth, and lab automation. Top holdings include AXGN (Axogen, ~3%), ARWR (Arrowhead Pharmaceuticals, ~2.6%), and TWST (Twist Bioscience, ~2.3%), with top 10 comprising ~23%. Sector allocation skews heavily to health technology (86%), with minor technology services (5%). The expense ratio is 0.68%. Its global, multi-cap design emphasizes innovation over mega-caps, with quarterly rebalancing to maintain thematic purity.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI), inception 2006, passively tracks the Dow Jones U.S. Select Medical Equipment Index, focusing on U.S. companies manufacturing diagnostic and therapeutic devices. It features 49 holdings, market-cap weighted for liquidity. Top holdings dominate: ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), SYK (Stryker, ~11%), with top 10 at ~75%. Nearly 100% allocated to health technology/medical devices. Expense ratio stands at 0.38%. This established fund prioritizes established device leaders, with rebalancing aligned to index methodology for efficient tracking.

Invesco S&P 500 Equal Weight Health Care ETF (RSPH) Overview

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH), launched 2006, is a smart beta passive ETF tracking the S&P 500 Equal Weight Health Care Index. It equally weights ~60 S&P 500 healthcare firms, rebalanced quarterly to mitigate mega-cap dominance. Top holdings like CNC (Centene, ~2.6%), HUM (Humana, ~2.5%), and UNH (UnitedHealth, ~2.3%) reflect uniformity, top 10 ~22%. Allocations: health technology (66%), health services (22%), distribution (6%). Expense ratio is 0.40%. This structure enhances mid-cap exposure within large-cap healthcare for broader diversification.

Industry and Thematic Landscape

The healthcare sector benefits from structural tailwinds like population aging, rising chronic diseases, and tech integration via AI, robotics, and precision medicine. Capital flows favor innovation amid regulatory stability post-COVID, though antitrust scrutiny on providers and drug pricing reforms pose risks. Macro drivers include lower interest rates boosting biotech funding, while earnings growth in devices and services outpaces pharma. Geopolitical tensions minimally impact U.S.-centric exposures, but supply chain issues for semiconductors affect medtech. Sector volatility stems from FDA approvals, M&A (mergers and acquisitions) activity, and reimbursement policies, creating opportunities across subsectors.

Performance and Positioning Comparison

In recent months, RSPH has shown trend consistency with its diversified blend, experiencing shallower drawdowns than tech-tilted peers amid market rotations. IHI's concentration in mega-cap devices like ISRG amplifies volatility to growth cycles but offers momentum in procedural volumes. HTEC, with smaller innovative holdings, displays higher relative volatility and sensitivity to biotech sentiment, leading to larger swings in recent market cycles. Performance divergences arise from RSPH's equal-weight risk diffusion versus IHI's cap-weighted stability and HTEC's thematic beta to innovation breakthroughs. RSPH suits lower concentration risk, IHI macro-resilient leaders, and HTEC high-conviction growth.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes like healthcare ETFs.

Tickeron AI Verdict

Tickeron’s AI favors RSPH with moderate probability due to its superior diversification (60 equal-weighted holdings), balanced cost efficiency (0.40% expense ratio), and stable momentum in broad healthcare cycles. While HTEC offers thematic upside and IHI liquidity advantages, RSPH's reduced concentration and risk-adjusted positioning better align with current structural strengths in diversified sector exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations